SlideShare una empresa de Scribd logo
1 de 16
Acute Lymphocytic Leukemia
 Leukemia is a type of cancer of the blood or
 bone marrow characterized by an abnormal
 increase of immature white blood cells
 called "blasts". Leukemia is a broad term
 covering a spectrum of diseases. In turn, it is
 part of the even broader group of diseases
 affecting the blood, bone marrow, and
 lymphoid system, which are all known as
 hematological neoplasms.
 In 2000, approximately 256,000 children
  and adults around the world developed
  some form of leukemia, and 209,000 died
  from it. About 90% of all leukemias are
  diagnosed in adults.
 Classification
 Clinically and pathologically, leukemia is
  subdivided into a variety of large groups.
  The first division is between its acute and
  chronic forms:
Four major kinds of leukemia

      Cell type               Acute                Chronic


Lymphocytic leukemia    Acute lymphoblastic   Chronic lymphocytic
 (or "lymphoblastic")    leukemia (ALL)         leukemia (CLL)




Myelogenous leukemia    Acute myelogenous     Chronic myelogenous
 (also "myeloid" or      leukemia (AML)         leukemia (CML)
 "nonlymphocytic")       (or myeloblastic)
Acute Lymphoblastic Leukemia
 Acute lymphoblastic leukemia (ALL) is a form of leukemia,
  or cancer of the white blood cells characterized by excess
  lymphoblasts.
 Malignant, immature white blood cells continuously
  multiply and are overproduced in the bone marrow. ALL
  causes damage and death by crowding out normal cells in
  the bone marrow, and by spreading (infiltrating) to other
  organs. ALL is most common in childhood with a peak
  incidence at 2–5 years of age, and another peak in old age.
  The overall cure rate in children is about 80%, and about
  45%-60% of adults have long-term disease-free survival
 Acute refers to the relatively short time course of
  the disease (being fatal in as little as a few weeks if
 left untreated) to differentiate it from the very
 different disease of chronic lymphocytic leukemia,
 which has a potential time course of many years. It
 is interchangeably referred to as Lymphocytic or
 Lymphoblastic. This refers to the cells that are
 involved, which if they were normal would be
 referred to as lymphocytes but are seen in this
 disease in a relatively immature (also termed
 'blast') state.
Cases of Acute Lymphocytic
 Leukemia are detected by:

Swelling in the abdomen
Enlarged lymph nodes
Bone or joint pain
Symptoms from an enlarged
 thymus
Tests Used to Look for ALL


 Blood tests
 Bone marrow aspiration and biopsy
 Lumbar puncture (spinal tap)
 Lymph node biopsy
Lab Tests Used to Diagnose and
    Classify ALL
 Blood cell counts and blood cell exam (peripheral
    blood smear)
   Blood chemistry and coagulation tests
   Routine exams under a microscope
   Cytochemistry
   Flow cytometry and immunohistochemistry
   Cytogenetics
   Fluorescent in situ hybridization (FISH)
   Polymerase chain reaction (PCR)
Risk Factors for ALL
 Radiation exposure
 Certain chemical exposures
    Chemotherapy drugs
    Benzene
 Certain viral infections
    Infection with human T-cell lymphoma/leukemia virus-1
     (HTLV-1)
    Epstein-Barr virus (EBV)
 Inherited syndromes
    Down syndrome
    Klinefelter syndrome
    Fanconi anemia
    Bloom syndrome
    Ataxia-telangiectasia
    Neurofibromatosis
 Race/ethnicity
   ALL is more common in whites than in
    African Americans
 Gender
   ALL is slightly more common in males than in females.
 Having an identical twin with ALL
 Uncertain, unproven or controversial risk factors
   Exposure to electromagnetic fields (such as living near
    power lines or using cell phones)
   Workplace exposure to diesel, gasoline, pesticides, and
    certain other chemicals
   Smoking
   Exposure to hair dyes
Statistics/Prevalence

 Statistics on acute lymphocytic leukemia based on
  rates from 2000 to 2002 indicate that 1 out of every 870
  people born today will be diagnosed with ALL at some
  point during their life. Other statistics show that the
  median age at diagnosis was 11 years of age and the
  median age at death was 47 years of age.
 The American Cancer Society estimated that 3,970
  people (2,180 men and 1,790 women) would be
  diagnosed with acute lymphocytic leukemia (acute
  lymphoblastic leukemia, or ALL) in 2005.
From 1998 to 2002, the median age at diagnosis for acute
lymphocytic leukemia was 11 years. The percentages of
people diagnosed with ALL based on age are:
    63.6 percent were diagnosed under age 20
    9.7 percent between 20 and 34
    5.8 percent between 35 and 44
    6.1 percent between 45 and 54
    5.3 percent between 55 and 64
    4.5 percent between 65 and 74
    3.4 percent between 75 and 84
    1.5 percent 85+ years of age.
The age-adjusted acute lymphocytic leukemia incidence rate
was 1.5 per 100,000 men and women per year.

From 1998 to 2002, the median age at death from acute
lymphocytic leukemia was 47 years of age. The percentages of
people who died from ALL based on age are:
       22.2 percent died under age 20
       15.7 percent between 20 and 34
       9.6 percent between 35 and 44
       10.7 percent between 45 and 54
       11.1 percent between 55 and 64
       12.9 percent between 65 and 74
       12.4 percent between 75 and 84
       5.6 percent 85+ years of age.
 The age-adjusted acute lymphocytic leukemia
  death rate was 0.5 per 100,000 men and women per
 year in the United States.

 The five-year relative survival rates by race and sex
  are:
      65.2 percent for Caucasian men
      66.7 percent for Caucasian women
      54.2 percent for African American men
      54.8 percent for African American women.

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Acute lymphoid leukemia (case presentation)
Acute lymphoid leukemia (case presentation)Acute lymphoid leukemia (case presentation)
Acute lymphoid leukemia (case presentation)
 
Acute leukemias 1-csbrp
Acute leukemias 1-csbrpAcute leukemias 1-csbrp
Acute leukemias 1-csbrp
 
Haematological malignancies
Haematological malignanciesHaematological malignancies
Haematological malignancies
 
Acute leukemia 2nd year students
Acute leukemia 2nd year studentsAcute leukemia 2nd year students
Acute leukemia 2nd year students
 
C H R O N I C M Y E L O P R O L I F E R A T I V E D I S O R D E R
C H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E RC H R O N I C  M Y E L O P R O L I F E R A T I V E  D I S O R D E R
C H R O N I C M Y E L O P R O L I F E R A T I V E D I S O R D E R
 
LUKEMIA
LUKEMIALUKEMIA
LUKEMIA
 
AML vs ALL 5th Semester
AML vs ALL 5th SemesterAML vs ALL 5th Semester
AML vs ALL 5th Semester
 
Haematological malignancies - part one
Haematological malignancies - part oneHaematological malignancies - part one
Haematological malignancies - part one
 
Acute leukemias 2-csbrp
Acute leukemias 2-csbrpAcute leukemias 2-csbrp
Acute leukemias 2-csbrp
 
Mpn
MpnMpn
Mpn
 
Leukemia
LeukemiaLeukemia
Leukemia
 
An introduction to haematological malignancies
An introduction to haematological malignanciesAn introduction to haematological malignancies
An introduction to haematological malignancies
 
leukemias
leukemiasleukemias
leukemias
 
No Title
No TitleNo Title
No Title
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Acute lymphoblastic leukemia dr narmada
Acute lymphoblastic leukemia dr narmadaAcute lymphoblastic leukemia dr narmada
Acute lymphoblastic leukemia dr narmada
 
Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute Myeloid Leukemia
Acute Myeloid Leukemia
 
Myeloproliferative disorder
Myeloproliferative disorderMyeloproliferative disorder
Myeloproliferative disorder
 
Acute Leukemia
Acute LeukemiaAcute Leukemia
Acute Leukemia
 
Hematological Malignancies 1/2
Hematological Malignancies 1/2Hematological Malignancies 1/2
Hematological Malignancies 1/2
 

Destacado

Destacado (10)

Acute Lymphoblastic Leukaemia
Acute Lymphoblastic LeukaemiaAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia
 
Acute Lymphoblastic Lymphoma
Acute Lymphoblastic LymphomaAcute Lymphoblastic Lymphoma
Acute Lymphoblastic Lymphoma
 
Acute Lymphoblastic Leukaemia
Acute Lymphoblastic LeukaemiaAcute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia
 
epstein-bar virus (EBV)
epstein-bar virus (EBV)epstein-bar virus (EBV)
epstein-bar virus (EBV)
 
Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
 
Muscle tone PBL MBBS
Muscle tone PBL MBBSMuscle tone PBL MBBS
Muscle tone PBL MBBS
 
Hematology (1) The blood and bone marrow, abnormal blood count, anemias: an o...
Hematology (1) The blood and bone marrow, abnormal blood count, anemias: an o...Hematology (1) The blood and bone marrow, abnormal blood count, anemias: an o...
Hematology (1) The blood and bone marrow, abnormal blood count, anemias: an o...
 
Acute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatmentAcute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatment
 
8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia
 
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia
 

Similar a Ward class ppt-intro

Similar a Ward class ppt-intro (20)

Leukemia , causes, clinical features, raktarbud
Leukemia , causes, clinical features, raktarbud Leukemia , causes, clinical features, raktarbud
Leukemia , causes, clinical features, raktarbud
 
Lukemia in children
Lukemia in children Lukemia in children
Lukemia in children
 
leukemias.ppt
leukemias.pptleukemias.ppt
leukemias.ppt
 
An update of Acute leukemia in children.ppt
An update of Acute leukemia in children.pptAn update of Acute leukemia in children.ppt
An update of Acute leukemia in children.ppt
 
LUEKEMIA by S .S. S.pptx
LUEKEMIA by S            .S.        S.pptxLUEKEMIA by S            .S.        S.pptx
LUEKEMIA by S .S. S.pptx
 
LEUKEMIA BY MWEBAZA VICTOR 2O23.pptx
LEUKEMIA BY MWEBAZA VICTOR 2O23.pptxLEUKEMIA BY MWEBAZA VICTOR 2O23.pptx
LEUKEMIA BY MWEBAZA VICTOR 2O23.pptx
 
Oncology disorder
Oncology disorderOncology disorder
Oncology disorder
 
Childhood leukemia long vr
Childhood leukemia  long vrChildhood leukemia  long vr
Childhood leukemia long vr
 
Introduction to leukemia
Introduction to leukemia Introduction to leukemia
Introduction to leukemia
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Leukaemia for bds
Leukaemia for bdsLeukaemia for bds
Leukaemia for bds
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemia
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemia
 
Myeloproliferative
MyeloproliferativeMyeloproliferative
Myeloproliferative
 
Myeloproliferative
MyeloproliferativeMyeloproliferative
Myeloproliferative
 
Ppt biol316 presentation
Ppt biol316 presentationPpt biol316 presentation
Ppt biol316 presentation
 
biology
biologybiology
biology
 
biology
biologybiology
biology
 
project
projectproject
project
 
bio
biobio
bio
 

Ward class ppt-intro

  • 2.  Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases affecting the blood, bone marrow, and lymphoid system, which are all known as hematological neoplasms.
  • 3.  In 2000, approximately 256,000 children and adults around the world developed some form of leukemia, and 209,000 died from it. About 90% of all leukemias are diagnosed in adults.  Classification  Clinically and pathologically, leukemia is subdivided into a variety of large groups. The first division is between its acute and chronic forms:
  • 4. Four major kinds of leukemia Cell type Acute Chronic Lymphocytic leukemia Acute lymphoblastic Chronic lymphocytic (or "lymphoblastic") leukemia (ALL) leukemia (CLL) Myelogenous leukemia Acute myelogenous Chronic myelogenous (also "myeloid" or leukemia (AML) leukemia (CML) "nonlymphocytic") (or myeloblastic)
  • 5. Acute Lymphoblastic Leukemia  Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by excess lymphoblasts.  Malignant, immature white blood cells continuously multiply and are overproduced in the bone marrow. ALL causes damage and death by crowding out normal cells in the bone marrow, and by spreading (infiltrating) to other organs. ALL is most common in childhood with a peak incidence at 2–5 years of age, and another peak in old age. The overall cure rate in children is about 80%, and about 45%-60% of adults have long-term disease-free survival
  • 6.  Acute refers to the relatively short time course of the disease (being fatal in as little as a few weeks if left untreated) to differentiate it from the very different disease of chronic lymphocytic leukemia, which has a potential time course of many years. It is interchangeably referred to as Lymphocytic or Lymphoblastic. This refers to the cells that are involved, which if they were normal would be referred to as lymphocytes but are seen in this disease in a relatively immature (also termed 'blast') state.
  • 7. Cases of Acute Lymphocytic Leukemia are detected by: Swelling in the abdomen Enlarged lymph nodes Bone or joint pain Symptoms from an enlarged thymus
  • 8. Tests Used to Look for ALL  Blood tests  Bone marrow aspiration and biopsy  Lumbar puncture (spinal tap)  Lymph node biopsy
  • 9. Lab Tests Used to Diagnose and Classify ALL  Blood cell counts and blood cell exam (peripheral blood smear)  Blood chemistry and coagulation tests  Routine exams under a microscope  Cytochemistry  Flow cytometry and immunohistochemistry  Cytogenetics  Fluorescent in situ hybridization (FISH)  Polymerase chain reaction (PCR)
  • 10. Risk Factors for ALL  Radiation exposure  Certain chemical exposures  Chemotherapy drugs  Benzene  Certain viral infections  Infection with human T-cell lymphoma/leukemia virus-1 (HTLV-1)  Epstein-Barr virus (EBV)
  • 11.  Inherited syndromes  Down syndrome  Klinefelter syndrome  Fanconi anemia  Bloom syndrome  Ataxia-telangiectasia  Neurofibromatosis  Race/ethnicity  ALL is more common in whites than in African Americans
  • 12.  Gender  ALL is slightly more common in males than in females.  Having an identical twin with ALL  Uncertain, unproven or controversial risk factors  Exposure to electromagnetic fields (such as living near power lines or using cell phones)  Workplace exposure to diesel, gasoline, pesticides, and certain other chemicals  Smoking  Exposure to hair dyes
  • 13. Statistics/Prevalence  Statistics on acute lymphocytic leukemia based on rates from 2000 to 2002 indicate that 1 out of every 870 people born today will be diagnosed with ALL at some point during their life. Other statistics show that the median age at diagnosis was 11 years of age and the median age at death was 47 years of age.  The American Cancer Society estimated that 3,970 people (2,180 men and 1,790 women) would be diagnosed with acute lymphocytic leukemia (acute lymphoblastic leukemia, or ALL) in 2005.
  • 14. From 1998 to 2002, the median age at diagnosis for acute lymphocytic leukemia was 11 years. The percentages of people diagnosed with ALL based on age are:  63.6 percent were diagnosed under age 20  9.7 percent between 20 and 34  5.8 percent between 35 and 44  6.1 percent between 45 and 54  5.3 percent between 55 and 64  4.5 percent between 65 and 74  3.4 percent between 75 and 84  1.5 percent 85+ years of age.
  • 15. The age-adjusted acute lymphocytic leukemia incidence rate was 1.5 per 100,000 men and women per year. From 1998 to 2002, the median age at death from acute lymphocytic leukemia was 47 years of age. The percentages of people who died from ALL based on age are:  22.2 percent died under age 20  15.7 percent between 20 and 34  9.6 percent between 35 and 44  10.7 percent between 45 and 54  11.1 percent between 55 and 64  12.9 percent between 65 and 74  12.4 percent between 75 and 84  5.6 percent 85+ years of age.
  • 16.  The age-adjusted acute lymphocytic leukemia death rate was 0.5 per 100,000 men and women per year in the United States.  The five-year relative survival rates by race and sex are:  65.2 percent for Caucasian men  66.7 percent for Caucasian women  54.2 percent for African American men  54.8 percent for African American women.